Le Lézard
Classified in: Health, Business
Subjects: PER, CXP

Sciton Announces the Launch of Direct Operations in the United Kingdom


PALO ALTO, Calif., Nov. 25, 2020 /PRNewswire/ -- Sciton® Inc., a leading manufacturer of medical and aesthetic lasers and light source technologies based in Palo Alto, California, USA, is pleased to announce the establishment of direct operations in the United Kingdom and Ireland.

Sciton, Because Results Matter

David Higham, an 8-year Sciton alum, has been promoted to Country Manager for the United Kingdom. He and his family are relocating to London to establish and lead Sciton's U.K. operations.

Sciton will be expanding its marketing, sales, clinical education and service offerings through direct operations. "The U.K. is an important market for Sciton's global growth strategy, and we look forward to introducing our innovative aesthetic technologies with an outstanding customer experience to match," said David Percival, Vice-President and General Manager for Sciton International.

Sciton will leverage the insight and expertise of the U.K.'s internationally renowned aesthetic physicians to strengthen their market position. "We are confident that our focused efforts will greatly benefit our U.K. customers.  We are also thrilled to introduce our JouleX platform with well-established treatments such as Halo and ClearV along with our new fractional treatment, MOXI, and BBL HERO, the biggest advancement in the history of pulsed light based technology," said Matthew Gelber, Director of Sciton - EMEA/LATAM.

ABOUT SCITON

Sciton, Inc., located in Palo Alto, California, is an employee-owned medical device company established in 1997 by co-founders Jim Hobart, Ph.D., and Dan Negus, Ph.D. Sciton is committed to providing best-in-class laser and light solutions for medical professionals who want superior durability, performance and value. Sciton offers aesthetic and medical devices for women's health, fractional and full-coverage skin resurfacing and skin revitalization, phototherapy, vascular and pigmentation lesions, scar reduction, acne, body contouring, and hair reduction. Sciton operates on a worldwide basis with direct sales teams in the United States, Canada, Australia, United Kingdom, Ireland, Japan and distributor partners in more than 45 countries. For more information, and a complete listing of Sciton systems, visit www.sciton.com.

Facebook: @ScitonInc
Instagram: @Sciton_Inc
LinkedIn: @ScitonInc

Logo - https://mma.prnewswire.com/media/385815/Sciton_Logo.jpg


These press releases may also interest you

at 00:00
Surrey physician, Dr. Sachit Shah, of Beautiful Canadian Laser and Skincare Clinic, has been approved as the first doctor in B.C. to offer non-surgical facelifts using a newer, Health Canada approved thread material. "This is a very fast and...

22 jan 2021
The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine's efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of...

22 jan 2021
The Alisal Guest Ranch and Resort has partnered with biosafety company R-Zero, incorporating the company's hospital-grade UV-C technology into its disinfection protocols to ensure a safe reopening for guests and staff amid the COVID-19 pandemic. The...

22 jan 2021
The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals' LupkynisTM (voclosporin) as the first oral treatment developed specifically for adults with active...

22 jan 2021
For the second time in less than two months, the U.S. Food and Drug Administration (FDA) has approved a new medication to treat adults with lupus nephritis (lupus-related kidney disease) in combination with a background immunosuppressive therapy...

22 jan 2021
Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has approved LUPKYNISTM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult...



News published on 25 november 2020 at 09:00 and distributed by: